CLDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Celldex Therapeutics Inc (CLDX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive long-term catalysts and analyst upgrades, the recent public offering has caused short-term price pressure. Additionally, the technical indicators and options data do not suggest immediate upside potential. It is better to hold off on buying until there is more clarity on the stock's recovery post-offering and further developments in its pipeline.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 52.966, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading close to its support level (S1: 29.014). The pre-market drop of -6.81% suggests further downside pressure.
The public offering will raise $300 million, strengthening the company's financial position for R&D and commercialization efforts.
The public offering at $29 per share has caused short-term price pressure, with the stock dropping -3.45% after-hours. Financial performance in Q4 2025 showed a significant revenue drop (-89.70% YoY), and the company remains unprofitable with a net income of -$81.3 million.
In Q4 2025, revenue dropped significantly by -89.70% YoY to $121,000. However, net income improved to -$81.3 million (up 72.68% YoY), and EPS increased to -1.22 (up 71.83% YoY). Gross margin remained stable at 100%.
Analysts are optimistic about the stock's long-term potential, with Wolfe Research upgrading it to Outperform and Stifel raising its price target to $68. Goldman Sachs and Morgan Stanley also raised their price targets, citing favorable risk/reward and upcoming catalysts in 2026.
